|Bid||83.81 x 300|
|Ask||84.50 x 500|
|Day's Range||84.01 - 84.49|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||31.69|
|Dividend & Yield||2.72 (3.27%)|
|1y Target Est||N/A|
Global markets were weighed down by comments from the ECB and Bank of Japan even as bullish GDP data emerged from China this week
Roche, Celgene and Novartis could change the multiple sclerosis landscape, a sector now dominated by Biogen.
The overall contribution of the Innovative Medicines segment was ~67.6% at $8.28 billion for 2Q17.